Donna S Neuberg

机构：Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center · ORCID：0000-0003-2566-3145

发表论文 1782 篇 · 总被引 104821 次 · h-index 158

代表论文

Azacitidine–Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia (2026 · New England Journal of Medicine · 被引 1)
Supplementary Table 1 from Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine (2026)
Figure S2 from Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine (2026)
Figure S3 from Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine (2026)
Supplementary Table 2 from Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine (2026)
Supplementary Table 4 from Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine (2026)